JonesResearch raised the firm’s price target on Wave Life Sciences to $16 from $12 and keeps a Buy rating on the shares. The company’s interim six-month dystrophin data in Duchenne muscular dystrophy patients amenable to Exon 53 skipping “look highly positive,” the analyst tells investors in a research note. The firm is bullish on Wave Life’s chances of FDA approval and increased its probability of sucess to 70% from 35%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences announces $175M ordinary shares, warrants offering
- Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences price target raised to $20 from $16 at Leerink
- Deere dips after Trump tariff threat, DOJ to sue Visa: Morning Buzz
- Wave Life Sciences price target raised to $22 from $15 at H.C. Wainwright